Drugs / CNTO 3157
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02008279 | Dec 2013 → Aug 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01704040 | Oct 2012 → Nov 2014 | — | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 1 | NCT01195207 | Jun 2010 → Jan 2012 | asthma | Centocor, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTO3157 | “We sought to evaluate an inhibitory mAb to Toll-like receptor 3, CNTO3157, on experimental HRV-16 inoculation in healthy subjects and asthmatic patients.” PMID 28734844 ↗ Jul 2017 |
| Action | Inhibit | “We sought to evaluate an inhibitory mAb to Toll-like receptor 3, CNTO3157, on experimental HRV-16 inoculation in healthy subjects and asthmatic patients.” PMID 28734844 ↗ Jul 2017 |
| Modality | Monoclonal antibody | “We sought to evaluate an inhibitory mAb to Toll-like receptor 3, CNTO3157, on experimental HRV-16 inoculation in healthy subjects and asthmatic patients.” PMID 28734844 ↗ Jul 2017 |
| Route | Intravenous | “CNTO 3157 will be administered by IV infusion.” NCT01195207 ↗ |
| Target | TLR3 | “We sought to evaluate an inhibitory mAb to Toll-like receptor 3, CNTO3157, on experimental HRV-16 inoculation in healthy subjects and asthmatic patients.” PMID 28734844 ↗ Jul 2017 |